A breast cancer therapy that blocks estrogen synthesis to activate cancer - killing genes sometimes loses its effectiveness
because the cancer takes over
epigenetic mechanisms, including permanent DNA
modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute (UPCI).